144 related articles for article (PubMed ID: 23252897)
1. Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?
Gomez AM; Willcox N; Molenaar PC; Buurman W; Martinez-Martinez P; De Baets MH; Losen M
Ann N Y Acad Sci; 2012 Dec; 1274():48-59. PubMed ID: 23252897
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis.
Gomez AM; Vrolix K; MartÃnez-MartÃnez P; Molenaar PC; Phernambucq M; van der Esch E; Duimel H; Verheyen F; Voll RE; Manz RA; De Baets MH; Losen M
J Immunol; 2011 Feb; 186(4):2503-13. PubMed ID: 21239719
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
Woodle ES; Alloway RR; Girnita A
Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibition for antibody-mediated rejection.
Everly JJ; Walsh RC; Alloway RR; Woodle ES
Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989
[TBL] [Abstract][Full Text] [Related]
5. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.
Neubert K; Meister S; Moser K; Weisel F; Maseda D; Amann K; Wiethe C; Winkler TH; Kalden JR; Manz RA; Voll RE
Nat Med; 2008 Jul; 14(7):748-55. PubMed ID: 18542049
[TBL] [Abstract][Full Text] [Related]
6. The state of therapy for removal of alloantibody producing plasma cells in transplantation.
Everly MJ; Terasaki PI
Semin Immunol; 2012 Apr; 24(2):143-7. PubMed ID: 22153981
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients.
Gomez AM; Willcox N; Vrolix K; Hummel J; Nogales-Gadea G; Saxena A; Duimel H; Verheyen F; Molenaar PC; Buurman WA; De Baets MH; Martinez-Martinez P; Losen M
J Immunol; 2014 Aug; 193(3):1055-1063. PubMed ID: 24973445
[TBL] [Abstract][Full Text] [Related]
8. Molecular profiles of proteasome inhibition in plasma cell dyscrasias.
Mitsiades CS
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S23-7. PubMed ID: 19795532
[TBL] [Abstract][Full Text] [Related]
9. Elimination of post-transplant donor-specific HLA antibodies with bortezomib.
Idica A; Kaneku H; Everly MJ; Trivedi HL; Feroz A; Vanikar AV; Shankar V; Trivedi VB; Modi PR; Khemchandani SI; Dave SD; Terasaki PI
Clin Transpl; 2008; ():229-39. PubMed ID: 19708459
[TBL] [Abstract][Full Text] [Related]
10. Abrogation of anti-HLA antibodies via proteasome inhibition.
Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
Expert Rev Anticancer Ther; 2005 Jun; 5(3):465-76. PubMed ID: 16001954
[TBL] [Abstract][Full Text] [Related]
12. [Proteasome inhibitors].
Saeki Y; Fukunaga K; Tanaka K
Nihon Rinsho; 2010 Oct; 68(10):1818-22. PubMed ID: 20954323
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitors in cancer therapy.
Orlowski RZ
Methods Mol Biol; 2005; 301():339-50. PubMed ID: 15917644
[TBL] [Abstract][Full Text] [Related]
14. The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo.
Diwan TS; Raghavaiah S; Burns JM; Kremers WK; Gloor JM; Stegall MD
Transplantation; 2011 Mar; 91(5):536-41. PubMed ID: 21283064
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitor therapy for antibody-mediated rejection.
Woodle ES; Walsh RC; Alloway RR; Girnita A; Brailey P
Pediatr Transplant; 2011 Sep; 15(6):548-56. PubMed ID: 21884344
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
17. Drug discovery and assay development in the ubiquitin-proteasome system.
Berkers CR; Ovaa H
Biochem Soc Trans; 2010 Feb; 38(Pt 1):14-20. PubMed ID: 20074028
[TBL] [Abstract][Full Text] [Related]
18. Sustained reduction of alloantibody secreting plasma cells and donor specific antibody with proteasome inhibition in mice.
Redfield RR; Lou Y; Rodriguez E; Rostami S; Parsons RF; Noorchashm H; Naji A; Abt PL
Transpl Immunol; 2013 Dec; 29(1-4):11-6. PubMed ID: 24103731
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience.
Moran E; Carbone F; Augusti V; Patrone F; Ballestrero A; Nencioni A
Semin Hematol; 2012 Jul; 49(3):270-6. PubMed ID: 22726551
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitors in lung cancer.
Scagliotti G
Crit Rev Oncol Hematol; 2006 Jun; 58(3):177-89. PubMed ID: 16427303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]